Scholarlink

<p>The disease course and outcome of COVID-19 greatly varies between individuals. To explore which biological systems may contribute to this variation, we examined how individual metabolites and three metabolic scores relate to COVID-19 outcomes in hospitalized COVID-19 patients. The metabolome of 346 patients was measured using the 1H-NMR Nightingale platform. The association of individual metabolomic features and multi-biomarker scores, i.e. MetaboHealth, MetaboAge, and Infectious Disease Score (IDS) (higher scores reflect poorer health), with in-hospital disease course, long-term recovery, and overall survival were analyzed. Higher values for the metabolites phenylalanine (HR = 1.33, CI = 1.14–1.56), glucose (HR = 1.37, CI = 1.16–1.62) and lactate (HR = 1.38, CI = 1.16–1.63) were associated with mortality. For all three metabolic scores, higher scores were significantly associated with higher odds of a poorer in-hospital disease course (MetaboHealth: OR = 1.61, CI = 1.29–2.02; ΔMetaboAge: OR = 1.42, CI = 1.16–1.74; IDS: OR = 1.55, 1.25–1.93) and with overall survival (MetaboHealth: HR = 1.57, CI = 1.28–1.92; ΔMetaboAge: HR = 1.34, CI = 1.15–1.57; IDS: HR = 1.56, CI = 1.27–1.93). MetaboHealth and ΔMetaboAge showed a stronger association in younger patients (&lt; 70 yrs.) than older patients. No clear patterns were found in associations between the three scores and measures of long-term recovery. In conclusion, the heterogeneity in disease course after SARS-COV2 infection may be explained either by generic biological frailty reflected by the three metabolomics scores or by glycemic control (glucose, lactate) and respiratory distress (phenylalanine).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Associations between metabolomic scores and clinical outcomes in hospitalized COVID-19 patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月11日

查看全文
  • Jens A. Venema,
  • Anna Kuranova,
  • Daniele Bizzarri,
  • Simon P. Mooijaart,
  • Angele P. M. Kerckhoffs,
  • Kitty Slieker,
  • Evertine J. Abbink,
  • Harmke A. Polinder-Bos,
  • Eline Slagboom,
  • Geeske Peeters,
  • Jacobijn Gussekloo,
  • Karel G. M. Moons,
  • Maarten van Smeden,
  • René J. F. Melis,
  • Petra J. M. Elders,
  • Jan Festen

摘要

The disease course and outcome of COVID-19 greatly varies between individuals. To explore which biological systems may contribute to this variation, we examined how individual metabolites and three metabolic scores relate to COVID-19 outcomes in hospitalized COVID-19 patients. The metabolome of 346 patients was measured using the 1H-NMR Nightingale platform. The association of individual metabolomic features and multi-biomarker scores, i.e. MetaboHealth, MetaboAge, and Infectious Disease Score (IDS) (higher scores reflect poorer health), with in-hospital disease course, long-term recovery, and overall survival were analyzed. Higher values for the metabolites phenylalanine (HR = 1.33, CI = 1.14–1.56), glucose (HR = 1.37, CI = 1.16–1.62) and lactate (HR = 1.38, CI = 1.16–1.63) were associated with mortality. For all three metabolic scores, higher scores were significantly associated with higher odds of a poorer in-hospital disease course (MetaboHealth: OR = 1.61, CI = 1.29–2.02; ΔMetaboAge: OR = 1.42, CI = 1.16–1.74; IDS: OR = 1.55, 1.25–1.93) and with overall survival (MetaboHealth: HR = 1.57, CI = 1.28–1.92; ΔMetaboAge: HR = 1.34, CI = 1.15–1.57; IDS: HR = 1.56, CI = 1.27–1.93). MetaboHealth and ΔMetaboAge showed a stronger association in younger patients (< 70 yrs.) than older patients. No clear patterns were found in associations between the three scores and measures of long-term recovery. In conclusion, the heterogeneity in disease course after SARS-COV2 infection may be explained either by generic biological frailty reflected by the three metabolomics scores or by glycemic control (glucose, lactate) and respiratory distress (phenylalanine).